Attached files
| file | filename |
|---|---|
| 10-K - 10-K - Accelerate Diagnostics, Inc | axdx-20201231.htm |
| EX-32 - EX-32 - Accelerate Diagnostics, Inc | axdx-12312020xexh32ng.htm |
| EX-31.2 - EX-31.2 - Accelerate Diagnostics, Inc | axdx-12312020xexh312ng.htm |
| EX-31.1 - EX-31.1 - Accelerate Diagnostics, Inc | axdx-12312020xexh311ng.htm |
| EX-21 - EX-21 - Accelerate Diagnostics, Inc | axdx-12312020xexh21ng.htm |
EXHIBIT 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in the following Registration Statements:
(1)Registration Statement (Form S-3 No. 333-252470) of Accelerate Diagnostics, Inc.,
(2)Registration Statement (Form S-8 No. 333-187439) pertaining to the 2012 Omnibus Equity Incentive Plan of Accelerate Diagnostics, Inc.,
(3)Registration Statement (Form S-8 No. 333-199992) pertaining to the 2012 Omnibus Equity Incentive Plan of Accelerate Diagnostics, Inc.,
(4)Registration Statement (Form S-8 No. 333-213072) pertaining to the 2016 Employee Stock Purchase Plan of Accelerate Diagnostics, Inc.,
(5)Registration Statement (Form S-8 No. 333-225585) pertaining to the 2012 Omnibus Equity Incentive Plan of Accelerate Diagnostics, Inc.,
(6)Registration Statement (Form S-8 No. 333-233185) pertaining to the 2012 Omnibus Equity Incentive Plan of Accelerate Diagnostics, Inc., and
(7)Registration Statement (Form S-8 No. 333-239052) pertaining to the 2012 Omnibus Equity Incentive Plan of Accelerate Diagnostics, Inc.
of our report dated March 1, 2021, with respect to the consolidated financial statements of Accelerate Diagnostics, Inc., included in this Annual Report (Form 10-K) for the year ended December 31, 2020.
/s/ Ernst & Young LLP
Phoenix, Arizona
March 1, 2021